KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Acadia Pharmaceuticals (ACAD) Receivables - Net (2016 - 2025)

Acadia Pharmaceuticals has reported Receivables - Net over the past 10 years, most recently at $121.5 million for Q4 2025.

  • Quarterly results put Receivables - Net at $121.5 million for Q4 2025, up 23.01% from a year ago — trailing twelve months through Dec 2025 was $121.5 million (up 23.01% YoY), and the annual figure for FY2025 was $121.5 million, up 23.01%.
  • Receivables - Net for Q4 2025 was $121.5 million at Acadia Pharmaceuticals, up from $115.8 million in the prior quarter.
  • Over the last five years, Receivables - Net for ACAD hit a ceiling of $121.5 million in Q4 2025 and a floor of $51.4 million in Q2 2021.
  • Median Receivables - Net over the past 5 years was $87.3 million (2023), compared with a mean of $83.3 million.
  • Biggest five-year swings in Receivables - Net: decreased 8.18% in 2022 and later skyrocketed 66.51% in 2023.
  • Acadia Pharmaceuticals' Receivables - Net stood at $64.4 million in 2021, then decreased by 3.37% to $62.2 million in 2022, then skyrocketed by 58.0% to $98.3 million in 2023, then increased by 0.48% to $98.7 million in 2024, then increased by 23.01% to $121.5 million in 2025.
  • The last three reported values for Receivables - Net were $121.5 million (Q4 2025), $115.8 million (Q3 2025), and $107.5 million (Q2 2025) per Business Quant data.